Defining a Safe Biopsy Deferral Strategy in Patients With Low-Risk or Equivocal MRI Findings Using Prostate-Specific Antigen-Based Metrics.
BACKGROUND Management of men with equivocal MRI findings remains uncertain, while low-risk MRI may still harbor clinically significant prostate cancer (csPCa). We examined whether prostate-specific antigen (PSA)-based measures could identify a low-risk subgroup suitable for biopsy deferral in patients with Prostate Ima...